Esperite announces its decision to oppose the Dutch Authority for the Financial Markets (AFM) who levied a fine on the company (amounting to EUR 312,500), regarding what the AFM deemed to be repeated delayed disclosures of financial figures between 2016 and 2019.
Esperite will use the legal period of six weeks to elaborate a substantiated answer to the AFM.
The company had on due course informed its shareholders of technical difficulties to publish on time.
When, in June 2019, the Company's Auditor terminated its PIE licence with the Netherlands Authority for the Financial Markets (AFM) the company was no longer in the position to continue and finalize the audit of 2018 annual report in the announced timing.
Esperite will dispute this decision in good faith and regrets the decision of the AFM.
Esperite wants a fair consideration and will fulfil its legal obligations.
ESPERITE is a diversified investment company group specialized in Immunotherapy, Regenerative Medicine and Precision Medicine. Established in 2000, Esperite is a holding company, listed at Euronext Amsterdam and Paris. ESPERITE invests in companies able to transform the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
ESPERITE provides early access to key information and knowledge, improving the way Science address human diseases and genetic disorders. ESPERITE attains the highest quality and ethical standards in the pursuit of its vision to bring the benefits of personalized medicine to society.
To learn more about the ESPERITE Group, or to book an interview with the CEO Frederic Amar: firstname.lastname@example.org or visit the websites at www.esperite.com